Canaccord Genuity Reiterates a 'Buy' on OraSure Technologies (OSUR); Catalysts on the Horizon

February 9, 2012 11:14 AM EST
Get Alerts OSUR Hot Sheet
Price: $3.74 --0%

Rating Summary:
    9 Buy, 8 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on OraSure Technologies (NASDAQ: OSUR) price target of $14.00.

Analyst, Jeffrey Frelick, said, "While still mostly a catalyst story, quarterly results were in line to slightly ahead of expectations. The Q1/12 revenue outlook of $21M appears soft due to substance abuse testing, but our bullish thesis remains intact...HCV waived sites yet to come...OSUR reported $800k of HCV sales, ahead of our $500k estimate, mostly to non-waived public health centers. OSUR continues to train its selling partners on OraQuick HCV, including physician distributors, Merck (NYSE: MRK) sales reps as well as Merck inside sales reps...We reduce 2012E sales to $100M."

For an analyst ratings summary and ratings history on OraSure Technologies click here. For more ratings news on OraSure Technologies click here.

Shares of OraSure Technologies closed at $11.00 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View